This proof-of-principle study to assess effects of different doses (mini and micro) of
subcutaneous glucagon analog Dasiglucagon (Zealand Pharma, Copenhagen, Denmark) on the change
in blood glucose concentration during moderate-intensity exercise in people with T1D.